

**AMENDMENTS TO THE CLAIMS**  
**PURSUANT TO REVISED 37 CFR § 1.121**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

Claims 1-34 (Cancelled)

35. (New) A formulation comprising: racemic 3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone and 3-chloromethylsulfonyl-7-fluoro-1-methyl-4-quinolone.
36. (New) A formulation comprising: (S)-(+)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone, in enantiomeric excess, and 3-chloromethylsulfonyl-7-fluoro-1-methyl-4-quinolone.
37. (New) The formulation, as claimed in claim 36, wherein said (S)-(+)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone is at least 90% of the enantiomeric excess.
38. (New) The formulation, as claimed in claim 36, wherein said (S)-(+)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone is at least 95% of the enantiomeric excess.
39. (New) A formulation comprising: (R)-(-)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone in enantiomeric excess and 3-chloromethylsulfonyl-7-fluoro-1-methyl-4-quinolone.
40. (New) The formulation, as claimed in claim 39, wherein said (R)-(-)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone is at least 90% of the enantiomeric excess.

41. (New) The formulation, as claimed in claim 39, wherein said (R)-(-)-3-chloromethylsulfinyl-7-fluoro-1-methyl-4-quinolone is at least 95% of the enantiomeric excess.